- Home
- DGII vs RCUS Comparison
DGII vs RCUS Comparison
Compare DGII & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- RCUS
- Stock Information
- Founded
- DGII 1985
- RCUS 2015
- Country
- DGII United States
- RCUS United States
- Employees
- DGII N/A
- RCUS N/A
- Industry
- DGII Computer peripheral equipment
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- RCUS Health Care
- Exchange
- DGII Nasdaq
- RCUS Nasdaq
- Market Cap
- DGII 1.3B
- RCUS 1.2B
- IPO Year
- DGII N/A
- RCUS 2018
- Fundamental
- Price
- DGII $38.14
- RCUS $20.29
- Analyst Decision
- DGII Buy
- RCUS Buy
- Analyst Count
- DGII 4
- RCUS 8
- Target Price
- DGII $38.75
- RCUS $26.50
- AVG Volume (30 Days)
- DGII 141.4K
- RCUS 1.3M
- Earning Date
- DGII 11-12-2025
- RCUS 10-28-2025
- Dividend Yield
- DGII N/A
- RCUS N/A
- EPS Growth
- DGII 147.46
- RCUS N/A
- EPS
- DGII 1.14
- RCUS N/A
- Revenue
- DGII $420,935,000.00
- RCUS $262,000,000.00
- Revenue This Year
- DGII $2.46
- RCUS N/A
- Revenue Next Year
- DGII $7.51
- RCUS N/A
- P/E Ratio
- DGII $33.98
- RCUS N/A
- Revenue Growth
- DGII N/A
- RCUS 6.07
- 52 Week Low
- DGII $22.39
- RCUS $6.50
- 52 Week High
- DGII $39.62
- RCUS $20.53
- Technical
- Relative Strength Index (RSI)
- DGII 58.43
- RCUS 74.90
- Support Level
- DGII $38.33
- RCUS $16.41
- Resistance Level
- DGII $39.62
- RCUS $20.53
- Average True Range (ATR)
- DGII 1.07
- RCUS 1.24
- MACD
- DGII 0.06
- RCUS 0.25
- Stochastic Oscillator
- DGII 78.04
- RCUS 94.98
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.